Pfizer Income from Continuous Operations 2012-2026 | PFE

Pfizer income from continuous operations for the twelve months ending March 31, 2026 was $7.522B, a 4.74% decline year-over-year.

  • Pfizer annual income from continuous operations for 2025 was $7.787B, a 3.28% decline from 2024.
  • Pfizer annual income from continuous operations for 2024 was $8.051B, a 270.67% increase from 2023.
  • Pfizer annual income from continuous operations for 2023 was $2.172B, a 93.08% decline from 2022.

Pfizer Income from Continuous Operations 2012-2026 | PFE

  • Pfizer annual income from continuous operations for 2025 was $7.787B, a 3.28% decline from 2024.
  • Pfizer annual income from continuous operations for 2024 was $8.051B, a 270.67% increase from 2023.
  • Pfizer annual income from continuous operations for 2023 was $2.172B, a 93.08% decline from 2022.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B